Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25195345 | 0.86 | AOC3 (0.47) | AOC3ACACBHDAC6 | |
| SCHEMBL25195344 | 0.86 | AOC3 (0.47) | AOC3ACACBHDAC6 | |
| SCHEMBL24184094 | 0.86 | AOC3 (0.47) | AOC3ACACBHDAC6 | |
| SCHEMBL17202082 | 0.83 | RBP4 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18539060 | 0.83 | CHRM4 (0.32) | ACACB | |
| SCHEMBL18150782 | 0.81 | SMO (0.40) | AOC3 | |
| SCHEMBL22084736 | 0.80 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18128074 | 0.80 | MTOR (0.31) | — | |
| SCHEMBL22733710 | 0.79 | MTOR (0.38) | ACACB | |
| SCHEMBL20796804 | 0.79 | HDAC6 (0.43) | AOC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-115916777-B | ATX inhibitor and preparation method and application thereof | 苏州爱科百发生物医药技术有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4180430-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ark Biopharmaceutical Co., Ltd (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-4180430-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ark Biopharmaceutical Co., Ltd (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-115916777-A | ATX inhibitor and preparation method and application thereof | 苏州爱科百发生物医药技术有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2022007882-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2022-01-13 | — | — | WO | disclosed |
| EP-3891158-A1 | MAP4K4 INHIBITORS | Imperial College of Science, Technology and Medicine (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | AOC3 3838/4885ACACB 886/4885HDAC3 1463/4885 |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATXN10, GCG, ATXN2L | AOC3 2866/4885ACACB 3126/4885HDAC3 2018/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | AOC3 3838/4885ACACB 886/4885HDAC3 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.